NCT03281200View on ClinicalTrials.gov

Chart Review Study to Describe the Clinical Profile of Idiopathic Pulmonary Fibrosis (IPF) Patients Treated With Nintedanib (OFEV®) in Real-world Practice in Spain

CompletedOBSERVATIONAL
Enrollment

172

Participants

Timeline

Start Date

October 24, 2017

Primary Completion Date

June 7, 2018

Study Completion Date

June 7, 2018

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

L - Antineoplastic and immunomodulating agents

L - Antineoplastic and immunomodulating agents

DRUG

L01 - Antineoplastic agents

L01 - Antineoplastic agents

DRUG

L01X - Other antineoplastic agents

L01X - Other antineoplastic agents

DRUG

L01XE - Protein kinase inhibitors

L01XE - Protein kinase inhibitors

DRUG

L01XE31 - Nintedanib

L01XE31 - Nintedanib

Trial Locations (1)

08029

Dynamic solutions, Barcelona

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT03281200 - Chart Review Study to Describe the Clinical Profile of Idiopathic Pulmonary Fibrosis (IPF) Patients Treated With Nintedanib (OFEV®) in Real-world Practice in Spain | Biotech Hunter | Biotech Hunter